Outcomes of bisphosphonate and its supplements for bone loss in kidney transplant recipients: a systematic review and network meta-analysis

Yang, Yan; Qiu, Shi; Deng, Linghui; Tang, Xi; Li, Xinrui; Wei, Qiang; Fu, Ping

doi:10.1186/s12882-018-1076-1

Table 1 Study characteristics

From: Outcomes of bisphosphonate and its supplements for bone loss in kidney transplant recipients: a systematic review and network meta-analysis

Study	Follow-up	Country	No. of Patients	Female/Male	Intervention	Bisphosphonate Administration	N	Co-intervention	Immunosuppression
Smerud 2012 [18]	12 months	Norway	129	30/99	ibandronate	3 mg i.v. (every 3 months)	66	PO calcium 500 mg tweice daily+ calcitriol 0.25 mcg daily	corticosteroids, MMF, CsA or FK506
Smerud 2012 [18]	12 months	Norway	129	30/99	placebo		63	PO calcium 500 mg tweice daily+ calcitriol 0.25 mcg daily	corticosteroids, MMF, CsA or FK506
Coco 2012 [19]	12 months	USA	42	15/27	risedronate	35 mg p.o. (weekly)	20	PO calcitriol 0.25 μg daily (with or without calcium)	corticosteroids, MMF, FK506, rapamycin
Coco 2012 [19]	12 months	USA	42	15/27	placebo		22	PO calcitriol 0.25 μg daily (with or without calcium)	corticosteroids, MMF, FK506, rapamycin
Torregrosa 2010 [20]	12 months	Spain	101	34/67	risedronate	35 mg p.o. (weekly)	52	PO calcium 1.5 g daily + vitamin D 400 IU daily	corticosteroids, FK506 with or without MMF
Torregrosa 2010 [20]	12 months	Spain	101	34/67	no treatment		49	PO calcium 1.5 g daily + vitamin D 400 IU daily	corticosteroids, FK506 with or without MMF
Torregrosa 2011 [21]	12 months	Spain	39	13/26	pamidronate	30 mg i.v. (between day 7 and 10 after KT and 3 months post-KT)	24	PO calcium 1 g daily + cholecalciferol 800 IU daily	corticosteroids, MMF, CsA
Torregrosa 2011 [21]	12 months	Spain	39	13/26	placebo		15	PO calcium 1 g daily + cholecalciferol 800 IU daily	corticosteroids, MMF, CsA
Walsh 2009 [22]	24 months	UK	125	24/69	pamidronate	1 mg/kg i.v. (perioperatively and at month 1, 4, 8, 12)	65	PO calcium 500 mg daily + vitamin D 400 IU daily	corticosteroids, CsA
Walsh 2009 [22]	24 months	UK	125	24/69	no treatment		60	PO calcium 500 mg daily + vitamin D 400 IU daily	corticosteroids, CsA
Lan 2008 [23]	6 months	China	46	27/19	alendronate	70 mg p.o. (weekly)	23	PO calcium 800 mg daily + calcitriol 0.25 μg daily	corticosteroids, MMF, CsA
Lan 2008 [23]	6 months	China	46	27/19	no treatment		23	PO calcium 800 mg daily + calcitriol 0.25 μg daily	corticosteroids, MMF, CsA
Trabulus 2008 [24]	12 months	Turkey	64	19/40	alendronate	10 mg p.o. (daily)	13	PO calcium 1 g daily	corticosteroids, azathioprin or MMF, CsA or FK506
					alfacalcidol	0.5 μg p.o. (daily)	25
					alendronate + alfacalcidol		17
					no treatment		9
Nayak 2007 [25]	6 months	India	50	NA	alendronate	35 mg p.o. (weekly)	27	PO calcium 1 g daily + vitamin D	NA
Nayak 2007 [25]	6 months	India	50	NA	no treatment		23	PO calcium 1 g daily + vitamin D	NA
El-Agroudy 2005 [26]	12 months	Egypt	60	0/60	alendronate	5 mg p.o. (daily)	15	PO calcium 500 mg daily	corticosteroids, CsA
					alfacalcidol	0.5 μg p.o. (daily)	15
					calcitonin	100 μl intranasally (p.o.d and stopped for 1 month every 3 month)	15
					no treatment		15
Schwarz 2004 [27]	36 months	Austria	20	8/12	zoledronic acid	4 mg i.v. (week 2, month 3)	9	PO calcium 1 g daily	corticosteroids, MMF, CsA
Schwarz 2004 [27]	36 months	Austria	20	8/12	placebo		10	PO calcium 1 g daily	corticosteroids, MMF, CsA
Jeffery 2003 [28]	12 months	Canada	117	26/71	alendronate	10 mg p.o. (daily)	57	PO calcium 500 mg daily	corticosteroids, CsA, azathioprin or MMF
Jeffery 2003 [28]	12 months	Canada	117	26/71	calcitriol	0.25 μg p.o. (daily)	60	PO calcium 500 mg daily	corticosteroids, CsA, azathioprin or MMF
Coco 2003 [29]	12 months	USA	72	28/31	pamidronate	60 mg i.v. (< 48 h after KT, 30 mg i.v. at months 1, 2, 3, 6)	36	calcium + calcitriol	corticosteroids, CsA or FK506
Coco 2003 [29]	12 months	USA	72	28/31	no treatment		36	calcium + calcitriol	corticosteroids, CsA or FK506
Hass 2003 [30]	6 months	Austria	20	8/12	zoledronic acid	4 mg i.v. (week 2, month 3)	10	PO calcium 1 g daily	corticosteroids, MMF, CsA
Hass 2003 [30]	6 months	Austria	20	8/12	placebo		10	PO calcium 1 g daily	corticosteroids, MMF, CsA
Grotz 2001 [31]	12 months	Germany	80	24/48	ibandronate	1 mg i.v. (just before KT, 2 mg i.v. at month 3, 6, 9)	36	PO calcium 500 mg daily	corticosteroids, MMF, CsA
Grotz 2001 [31]	12 months	Germany	80	24/48	no treatment		36	PO calcium 500 mg daily	corticosteroids, MMF, CsA
Nam 2000 [32]	6 months	South Kore	50	21/29	pamidronate	30 mg i.v. (every 4 weeks)	15	PO calcium 500 mg daily	NA
					calcitriol	0.5 μg p.o. (daily)	15
					no treatment		20
Grotz 1998 [33]	12 months	Germany	46	17/29	clodronate	800 mg p.o. (daily) for 14 days, each followed by 75 days without treatment	15	PO calcium 500 mg daily	corticosteroids, CsA
					calcitonin	100 IU intranasally twice a day	16
					no treatment		15
Giannini 2001 [34]	12 months	Italy	40	13/27	alendronate	10 mg p.o. (daily)	20	PO calcium 500 mg daily + calcitriol 0.5 μg daily	corticosteroids, CsA with or without azathioprin
Giannini 2001 [34]	12 months	Italy	40	13/27	no treatment		20	PO calcium 500 mg daily + calcitriol 0.5 μg daily	corticosteroids, CsA with or without azathioprin
Koc 2002 [35]	12 months	Turkey	35	10/25	alendronate	10 mg p.o. (daily)	8	PO calcium 1 g daily	corticosteroids, azathioprin, CsA
					calcitriol	0.5 μg p.o. (daily)	8
					no treatment		8
Torregrosa 2007 [36]	12 months	Spain	84	42/42	risedronate	35 mg p.o. (weekly)	39	PO calcium 2.5 g daily + vitamin D	corticosteroids, CsA or FK506, with or without MMF
Torregrosa 2007 [36]	12 months	Spain	84	42/42	no treatment		45	PO calcium 2.5 g daily + vitamin D	corticosteroids, CsA or FK506, with or without MMF

KT: kidney transplantation; i.v.: intravenous; p.o., PO: peros; p.o.d: per other day; N: numbers; NA: not available; MMF: mycophenolate mofetil; CsA: cyclosporine; FK506: tacrolimus; AZA: azathioprine; mTOR: mammalian target of rapamycin

Back to article page

ISSN: 1471-2369

Contact us

Submission enquiries: bmcnephrology@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Nephrology

Contact us